NCT06283303 2024-02-29
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Unknown
Clinical Trials
27 trialsNCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT06200363 2024-01-11
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT05370807 2023-10-24
RegoMel
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT05818267 2023-07-14
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
Changhai Hospital
Phase NA Unknown
NCT02365441 2023-07-07
ALT GIST
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT05382741 2023-05-17
VIVA
Ospedale Policlinico San Martino
Phase 2 Unknown
NCT02619435 2023-03-24
STREAM
National Cancer Institute, Naples
Phase 2 Unknown
NCT04030260 2023-03-23
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT05535647 2022-09-10
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05524155 2022-09-01
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05485909 2022-08-03
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
Sun Yat-sen University
Phase 2 Unknown
NCT05426811 2022-06-29
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
China Medical University, China
Phase 1/2 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT02773524 2022-01-13
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
Phase 3 Unknown
NCT05130021 2021-12-06
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Maxinovel Pty., Ltd.
Phase 2 Unknown
NCT02501551 2021-04-05
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Yonsei University
Phase 2 Unknown
NCT04819516 2021-03-29
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT03946917 2020-05-12
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT04008511 2019-07-05
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
China Medical University, China
Phase 1/2 Unknown
NCT03880877 2019-03-21
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 2 Unknown
NCT01949194 2018-08-10
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Jewish General Hospital
Phase 2 Unknown
NCT02288078 2014-11-13
Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
Clinical Research Support Center Kyush
Phase 2 Unknown
NCT01189903 2014-01-28
Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
National University Hospital, Singapore
Phase 2/3 Unknown